Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biden to bolster COVID-19 vaccine production with Defense Production Act

By Brian Buntz | December 29, 2020

coronavirus COVID-19 vaccine Pfizer

Image by Markus Winkler on Unsplash

Joe Biden is reportedly planning on invoking the Defense Production Act to shore up the production of COVID-19 vaccines in the U.S. 

While FDA has authorized the distribution of vaccines from Moderna Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX), distribution has been patchy thus far.

The news came from Dr. Celine Gounder, a Biden advisor, in a CNBC interview. “The idea there is to make sure the personal protective equipment, the test capacity and the raw materials for the vaccines are produced in adequate supply,” Gounder said. 

Biden announced a plan to ensure that 100 million vaccine shots are administered to Americans within his first 100 days in office, suggesting that, with the available vaccines requiring two shots, approximately 50 million people would be vaccinated across that 100-day period, according to a New York Times report.

The President-elect also criticized the current execution of the vaccine rollout under the Trump Administration’s Operation Warp Speed, warning that, at the current pace, vaccinating the entire country would “take years, not months,” despite the fact that health officials have touted that the average American could be vaccinated within months.

Secretary of Health and Human Services Alex Azar anticipates COVID-19 vaccines to be widely available in the second quarter of 2021. 

Using the Defense Production Act would enable the president to force companies to prioritize production of the vaccines. 

The U.S. government has a contract with Pfizer to procure 200 million doses and an additional 200 million doses from Moderna by July 31, 2021. The U.S. plans on procuring extra vaccine doses from AstraZeneca (LON:AZN) and others. 

Pfizer has also requested that the U.S. government invoke the Defense Production Act to improve its access to roughly nine specialized raw materials needed to manufacture the vaccine, according to the New York Times. The U.S. agreed, according to the publication, which cited anonymous sources. 

The Trump administration has already invoked the Defense Production Act times to beef up the production of COVID-19–related pharmaceuticals and personal protective equipment. 

President Trump vowed on Dec. 8 to use the law as necessary to ramp up vaccine production, according to Bloomberg.  

The U.S. government enacted the Defense Production Act in 1950 in response to the Korean War.  

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

Eli Lilly Huntsville Alabama Facility rendering (1)
Eli Lilly to build new $6B API manufacturing facility in Alabama
Thermo Fisher Scientific
Thermo Fisher expands investment in Asia bioprocessing for biopharma production
AstraZeneca
AstraZeneca to invest $2B in Maryland, support 2,600 jobs
This is the logo of Novartis.
Novartis opens new manufacturing plant in California
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE